Philips spotlights integrated diagnostics in oncology at ASCO 2019
May 30 2019 - 8:00AM
May 30, 2019
Philips oncology solutions provide deeper insights for cancer
teams to make better informed decisions and deliver more confident
paths to treatment
Amsterdam, the Netherlands and Chicago, Illinois
– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, will showcase its end-to-end oncology solutions
at the American Society of Clinical Oncology (ASCO) annual meeting,
May 31 – June 4 in Chicago. Visitors to the Philips booth
(#2122) at ASCO will experience Philips’ Oncology platform for
integrated diagnostics and therapy selection to drive clinical,
operational and financial benefits to achieve better health
outcomes, improve patient and staff experience and lower cost of
care.
In 2018, there were 18.1 million cases of cancer reported
globally, accounting for 9.6 million deaths around the world [1],
while the economic impact of cancer is significant and is
increasing. The total annual cost of cancer in 2010 was estimated
at approximately US$ 1.16 trillion [2]. As a leader in
oncology care and informatics, Philips is uniquely positioned to
deliver integrated oncology solutions to enable earlier and more
precise diagnosis and better clinical decision-support through
seamless multi-disciplinary assessment, to help care teams
determine the most appropriate care for a patient to improve
outcomes.
“While significant strides have been made in oncology over the
past decade, treating cancer is more complex than ever before. As
new data sources emerge providing input ranging from new drug
options to genomics, clinicians continue to struggle to leverage
the right information at the right time to develop and implement
precision medicine programs for personalized cancer care,” said
Louis Culot, General Manager of Oncology Informatics and Genomics
at Philips. “At Philips, we’re focused on delivering intelligent,
integrated oncology solutions to drive faster and more efficient
precise therapies, earlier response assessment and care plan
adjustment, to help improve outcomes across multiple disciplines
and clinical settings.”
Philips end-to-end oncology solutions In Booth
#2122 at ASCO, Philips will spotlight its vendor agnostic
technology to enable data gathering and aggregation from any
source, including external and internal labs, clinical data from
the EHR, annotation from multiple providers, internal and external
trial sources and more. Philips will also showcase its capabilities
to provide access to top-tier expert content for oncology decision
making from Dana-Farber Pathways, Academic Medical Center, which
includes optional personalized therapies listing and recommended
clinical trials matching according to genomic mutations.
Philips is unique in facilitating oncology pathways, molecular
tumor boards, and cancer care synopsis all on the same system.
“When treating cancer, personalization is critical. By teaming
with Philips, we can provide an umbrella of guidance and trust from
Dana-Farber to other locations and institutions around the country
and around the world where patients receive care,” said David
Jackman, MD, Medical Director for Clinical Pathways at the
Dana-Farber Cancer Institute. “Since 85% of cancer care happens in
community hospitals, providing access to information and guidance
is helpful to an oncologist outside of our Dana-Farber network, and
valuable for patients, since they know they are getting input from
a world-class facility.”
Philips Oncology Solutions spotlight at
ASCOPhilips will focus on three key areas featuring
Detection and Monitoring; Precision Diagnostics; and Therapy
Decision-Support. Visitors will experience intelligent, integrated
oncology solutions to support and enhance:
- Diagnosis, staging, and tumor progression tracking
- Biological tumor characterization
- Molecular and Multidisciplinary Tumor Board collaboration
- Patient
stratification, therapy prioritization, selection
and trial matching
- Radiation therapy simulation, planning and workflow
management
In booth #2122 at ASCO, Philips will showcase key solutions
across its oncology portfolio including:
- Oncology Pathways – high-quality, detailed,
evidence-based oncology treatment protocols powered by Dana-Farber,
allows clinical users to navigate through the branches of the
pathways to make clinical decisions and provide treatment plan
recommendations, including clinical trials.
- Oncology Platform [3] – comprehensive platform
integrates data from hospital information systems across different
clinical domains including radiology, pathology, and genomics, to
enable a detailed view of the patient and care path to facilitate
cross-disciplinary collaboration and communication.
- Pathology – Philips IntelliSite Pathology
Solution is the first and only digital pathology solution in the
U.S. to be marketed for primary diagnostic use to reduce pressure
on pathology services by streamlining workflows and extending
collaboration to help increase diagnostic confidence.
- Genomics [4] – end-to-end precision medicine
platform automates pathologists’ workflows through collaboration
with oncologists and peers, enabling genomic interpretation based
on a single, comprehensive patient view, which also includes
OncoSignal [5], signaling pathway activity analysis to reveal
tumor-driving mechanisms.
- Radiation Oncology Portfolio - radiation
oncology solutions designed to help improve and accelerate the
radiation oncology workflow from patient referral to treatment, to
support confident therapy decision-making, maximize value, and
improve the patient experience.
For more information on Philips’ vision for integrated
oncology, visit Philips at Booth #2122 at ASCO and follow
@PhilipsLiveFrom for #ASCO19 updates throughout the event.
[1] GLOBOCAN 2018 database:
https://www.who.int/cancer/PRGlobocanFinal.pdf . [2]
http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014
.[3] Not available for sale in all countries.[4] Not available for
sale in all countries.[5] For research use only; not for use in
diagnostic procedures.
For further information, please contact:
Kathy O’ReillyPhilips Group Press OfficeTel.: +1
978-221-8919E-mail : kathy.oreilly@philips.comTwitter:
@kathyoreilly
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips' health technology portfolio generated 2018
sales of EUR 18.1 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024